Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)

INTRODUCTION: Prophylactic treatment of severe hemophilia A is burdensome, requiring frequent intravenous injections. Extended half-life (EHL) factor VIII replacement therapies offer longer intervals between infusions while still meeting efficacy and safety outcomes; however, patient perspectives fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wells, Jane R., Gater, Adam, Marshall, Chris, Tritton, Theo, Vashi, Parth, Kessabi, Sophia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884429/
https://www.ncbi.nlm.nih.gov/pubmed/31313270
http://dx.doi.org/10.1007/s40271-019-00374-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884429/
https://www.ncbi.nlm.nih.gov/pubmed/31313270
http://dx.doi.org/10.1007/s40271-019-00374-x

Ejemplares similares